Technical Analysis for DRRX - DURECT Corporation

Grade Last Price % Change Price Change
grade C 0.6029 0.45% 0.00
DRRX closed up 0.45 percent on Friday, May 24, 2019, on 1.88 times normal volume. It ran into resistance at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical DRRX trend table...

Date Alert Name Type % Chg
50 DMA Resistance Bearish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Stochastic Reached Oversold Weakness 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Fell Below 20 DMA Bearish 0.45%
Fell Below 50 DMA Bearish 0.45%
MACD Bearish Signal Line Cross Bearish 0.45%
Expansion Pivot Sell Setup Bearish Swing Setup 0.45%
Wide Bands Range Expansion 0.45%

Older signals for DRRX ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

DURECT Corporation, a specialty pharmaceutical company, develops pharmaceutical systems technologies based on its proprietary drug delivery technology platforms. It focuses on the development of products for the treatment of various chronic and episodic disease areas, such as pain, central nervous system disorders, cardiovascular disease, and other chronic diseases. The company manufactures and sells ALZET osmotic pumps used in laboratory research; and a range of LACTEL standard and custom biodegradable polymers and excipients used as raw materials for the pharmaceutical and medical device clients. Its product pipeline includes REMOXY, an oral oxycodone gelatin capsule for chronic pain, which has received complete response letter from the U.S. Food and Drug Administration (FDA); POSIDUR, a Phase III clinical trial release formulation of bupivacaine for the treatment of post-surgical pain; ELADUR, a Phase II transdermal bupivacaine patch intended to provide delivery of bupivacaine; and TRANSDUR, a Phase II transdermal sufentanil patch intended to provide delivery of sufentanil. The company's products pipeline also comprises ORADUR-based opioids, including hydrocodone and hydromorphone for the treatment of pain, which are in Phase I clinical trial; oxymorphone, an ORADUR-based opioid for which IND has been accepted by the FDA; ORADUR-ADHD, a drug candidate in Phase I clinical trial for the treatment of attention deficit hyperactivity disorder; and Relday, an injectable risperidone product in Phase I clinical trial used to treat the symptoms of schizophrenia and bipolar I disorder. It is also involved in developing various biologics programs/research programs in other therapeutic categories. DURECT Corporation has strategic agreements with Hospira, Inc., Nycomed Danmark ApS; Pain Therapeutics, Inc.; Zogenix, Inc.; and Pfizer Inc. The company was founded in 1998 and is headquartered in Cupertino, California.
Pharmaceutical Pain Chemical Compounds Organic Compounds Schizophrenia Euphoriants Cardiovascular Disease Chronic Pain Central Nervous System Disorders Morphinans Attention Deficit Hyperactivity Disorder Ethers Opioids Phenols Chronic Diseases Fentanyl Drug Delivery Technology Treatment Of Attention Deficit Hyperactivity Disorder Hydromorphone Oxymorphone Sufentanil
Is DRRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 2.25
52 Week Low 0.46
Average Volume 552,820
200-Day Moving Average 0.8367
50-Day Moving Average 0.6644
20-Day Moving Average 0.6916
10-Day Moving Average 0.6914
Average True Range 0.0767
ADX 21.54
+DI 15.9574
-DI 20.8473
Chandelier Exit (Long, 3 ATRs ) 0.6699
Chandelier Exit (Short, 3 ATRs ) 0.7501
Upper Bollinger Band 0.8778
Lower Bollinger Band 0.5054
Percent B (%b) 0.26
BandWidth 53.846154
MACD Line 0.0033
MACD Signal Line 0.0162
MACD Histogram -0.0129
Fundamentals Value
Market Cap 88.62 Million
Num Shares 147 Million
EPS -0.26
Price-to-Earnings (P/E) Ratio -2.32
Price-to-Sales 7.10
Price-to-Book 0.00
PEG Ratio -0.16
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.72
Resistance 3 (R3) 0.74 0.71 0.70
Resistance 2 (R2) 0.71 0.68 0.70 0.70
Resistance 1 (R1) 0.66 0.66 0.64 0.64 0.69
Pivot Point 0.63 0.63 0.62 0.62 0.63
Support 1 (S1) 0.58 0.60 0.56 0.56 0.52
Support 2 (S2) 0.55 0.58 0.54 0.51
Support 3 (S3) 0.50 0.55 0.50
Support 4 (S4) 0.48